October 26 - 30, 2017
Pennsylvania Convention Center
Philadelphia, Pennsylvania, USA
Abstract submission deadline: Thursday, September 7
Advance registration deadline: Friday, September 22
Accreditation StatementThe American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation StatementThe AACR has designated this live activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) CreditPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Monday, December 11, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
REQUEST FOR CREDIT SURVEY
Statement of Educational Need, Target Audience, and Learning ObjectivesMolecularly targeted therapies have achieved great success from the "early days" of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases, and proteasome inhibitors. However, for each of these success stories, new challenges arise in terms of resistance, further refinement of these "targeted therapies" based on molecular sub-classification, and the opportunity to develop new combination therapies, especially with new immunotherapies.
Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Some researchers are focusing efforts on the unique set of molecular targets produced by the patient's tumor, regardless of disease site. Targeted cancer therapies also hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, and improving quality of life.
During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Physicians need to understand the latest research in the areas of cellular immunotherapy, mutation profiling, immune checkpoints and checkpoint blockade, targeting RAS, systems biology, radiomics, epigenetics, metabolism and the tumor microenvironment.
Discussions will spur new collaborations and provide guidance on future treatment opportunities for patients.
After participating in this CME activity, physicians should be able to:
Disclosure StatementIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the meeting app, online planner, or conference website and is available for download.
Acknowledgement of Financial or Other SupportThis activity is supported by grants and will be disclosed at the activity.
Questions about CME?Please contact the Office of CME at 215-440-9300 or firstname.lastname@example.org.